RxSight, Inc. (RXST)
NASDAQ: RXST · Real-Time Price · USD
6.57
+0.31 (4.95%)
At close: Aug 10, 2026, 4:00 PM EDT
6.58
+0.01 (0.15%)
After-hours: Aug 10, 2026, 7:34 PM EDT
RxSight Revenue
RxSight had revenue of $33.74M in the quarter ending June 30, 2026, with 0.31% growth. This brings the company's revenue in the last twelve months to $127.58M, down -13.24% year-over-year. In the year 2025, RxSight had annual revenue of $134.48M, down -3.89%.
Revenue (ttm)
$127.58M
Revenue Growth
-13.24%
P/S Ratio
2.14
Revenue / Employee
$276,751
Employees
461
Market Cap
273.27M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 134.48M | -5.45M | -3.89% |
| Dec 31, 2024 | 139.93M | 50.85M | 57.09% |
| Dec 31, 2023 | 89.08M | 40.07M | 81.77% |
| Dec 31, 2022 | 49.01M | 26.41M | 116.90% |
| Dec 31, 2021 | 22.59M | 7.92M | 53.92% |
| Dec 31, 2020 | 14.68M | 12.44M | 554.98% |
| Dec 31, 2019 | 2.24M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Treace Medical Concepts | 205.31M |
| Quanterix | 144.98M |
| InfuSystem Holdings | 143.34M |
| Standard BioTools | 84.60M |
| AVITA Medical | 75.63M |
| Electromed | 71.75M |
| 908 Devices | 57.80M |
| TriSalus Life Sciences | 45.08M |
RXST News
- 18 hours ago - RxSight price target lowered to $7 from $8 at Stifel - TheFly
- 4 days ago - RxSight price target raised to $6.30 from $5.50 at UBS - TheFly
- 4 days ago - RxSight says withdrawing guidance, will resume formal guidance in 2027 - TheFly
- 5 days ago - RxSight reports Q2 adjusted EPS (11c), consensus (19c) - TheFly
- 5 days ago - RxSight Earnings Call Transcript: Q2 2026 - Transcripts
- 5 days ago - RxSight Earnings release: Q2 2026 - Filings
- 5 days ago - RxSight Quarterly report: Q2 2026 - Filings
- 5 days ago - RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook - GlobeNewsWire